Orthopaedic surgery in severe bleeding disorders: A low-volume, high-cost procedure

Haemophilia

Volumn 8, Issue 6, 2002, Pages 809-814

  Mishra, V ^a   Tjonnfjord G E ^b   Paus, A C ^a   Vaaler, S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Rikshospitalet   (Norway)

Author keywords

Coagulation factor concentrates; Haemophilia; Hospitalization cost; Orthopaedic surgery; Reimbursement

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CEFUROXIME; OCTANATE; OCTANOIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ANKLE INJURY; ARTHROPATHY; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; DRUG COST; ELBOW DISEASE; ELECTIVE SURGERY; FOLLOW UP; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE PERSONNEL; HEMOPHILIA A; HEMOPHILIA B; HOSPITAL COST; HUMAN; INCOME; INTRAOPERATIVE PERIOD; KNEE DISEASE; LABORATORY TEST; LENGTH OF STAY; NORWAY; ORTHOPEDIC SURGERY; PHYSICAL ACTIVITY; POSTOPERATIVE INFECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 0036860463     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00691.x     Document Type: Article

References (16)

1. Nilsson IM, Berntorp E et al. Twenty five years of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
2. Teigland JC, Tjønnfjord GE, Evensen SA, Charania B. Knee arthroplasty in hemophilia: 5-12 year follow-up of 15 patients. Acta Orthop Scand 1993; 64 (2): 153-6.
3. Teigland JC, Tjønnfjord GE, Evensen SA, Charania B. Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients. J Intern Med 1994; 235: 239-43.
4. Heeg M, Meyer K, Smid WM, van Horn JR, van der Meer J. Total knee and hip arthroplasty in haemophilic patients. Haemophilia 1998; 4: 747-51.
5. Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement in haemophilia A. Haemophilia 2000; 6: 104-9.
6. Noord P, Hagen T. The Norwegian health care system OECD report. ECO/WKP. 1998; 98: 11.
7. Bohn RL, Colowick AB et al. Probabilities, cost and outcomes: methodological issues in modelling haemophilia treatment. Haemophilia 1999; 5: 374-7.
8. Hadley J, Zuckerman S. Determinants of hospital costs. Urban Institute Press Report 91-10, Washington DC, 1991.
9. Mishra V, Skeie BMHA, Vaaler S, Amlie E. A comparison of actual registered costs and cost derived from diagnosis-related groups (DRGs) for patient undergoing heart transplantation, lung transplantation and thoracotomy for other lung diseases. Transplantation Int 2001; 14: 361-9.
10. Mishra V, Vaaler S, Brinch L, Hagen TP. A prospective cost evaluation of costs related to allogen haemopoietic stem cell transplantation including pre-transplant procedures, transplantation and one year follow up procedures. Bone Marrow Transplant 2001; 28 (12): 1111-6.
11. Small M, Steven MM, Freeman PA, Lowe GDO, Belch JJF et al. Total knee arthroplasty in haemophilic arthritis. J Bone Joint Surg Br 1983; 65: 163-5.
12. The Danish Ministry of Health. Hospital funding and casemix 1999. 8 Nytt Nortdisk forslag. Denmark: Arnold Busck, 1999.
13. Minners AH, Sabin CA et al. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia ans severe von Willebrand disease. J Intern Med 1998; 244: 515-22.
14. Ministry of Health and Social Welfare. Patient DRG price list 1999. Oslo, Norway: Ministry of Health, 1999.
15. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-9.
16. Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.